First Annual OurCrowd Maimonides Award for Lifetime Achievement in Science, Leadership and Menschlichkeit, was given this year to Dr. Morry Blumenfeld
Feb 1, 2018 Dr. Morry Blumenfeld, a legend in the field of medical technology development as well as MedTech investment, was given the First Annual
The 2018 OurCrowd Global Investment Summit highlighted Israeli Digital Health Technologies
Feb 5, 2018 OurCrowd, one of the largest investment crowdfunding platforms in the world, held their annual summit at the International Convention Center in Jerusalem February 1.
Opportunities for Israeli Companies in Mexico and California
Here are the Highlights of the Cali-Israel-Mexico Innovation Expo Recruitment Presentation January 24th, 2018, Jerusalem Israel. JLM-BioCity, JBNF, Regus Co-Working Space, and the Cali-Israel-Mexico Innovation
JLM based Entera Bio sets terms for $60m Nasdaq IPO
DNA Biomedical Solutions Ltd. (TASE: DNA) subsidiary Entera Bio has set the terms for a Nasdaq IPO to raise $50 million – $60 million at a company valuation
Oramed Pharma’s CEO Issues Letter to Shareholders
Jan 19, 2017 Dear Shareholders, All the hard work and dedication in 2017 has successfully positioned Oramed to initiate a U.S. based multicenter 90-day treatment
OrCam Launched Next Generation of Artificial Vision for the Visually Impaired
Janaury 7, 2017 OrCam displayed their artificial vision technology, OrCam MyEye 2.0, at CES 2018. MyEye was been named a CES Innovation Awards honoree and a finalist in the last gadget standing
JLM based Salignostics Ltd is carrying out free saliva based pregnancy tests for a limited period of time
Dec 14, 2017 JLM based Salignostics Ltd has developed a novel pregnancy rapid home- test utilizing saliva. This is the first saliva pregnancy OTC product
Kitov Pharmaceuticals Announces Receipt of FDA’s Favorable Response to NT219’s pre-IND Meeting Package
Nov 11, 2017 – NT219 works by overcoming drug resistance of pancreatic cancer to various oncology drugs. Kitov Pharmaceuticals (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical
Granalix BioTechnologies, founded by Prof Ruth Gabizon, is marketing a Novel Food Additive Based On Pomegranate Oil For Protection From Neurodegenerative Diseases
Granalix BioTechnologies, following its commercial launch last year of GranaGard™ a food supplement based on pomegranate oil that was shown to prevent neurodegeneration diseases in mouse models,
